30 November 2017

 Clinigen Group plc

("Clinigen" or the "Group")

Total Voting Rights and Capital

In conformity with Rule 5.6.1 of the Disclosure Guidance and Transparency Rules, the Group notifies the market that as at 30 November 2017 Clinigen's issued share capital consists of 122,268,158 ordinary shares of 0.1 pence each with voting rights.  No shares are held in Treasury.

The above figure of 122,268,158 may be used by shareholders as the denominator to determine if they are required to notify their interests in, or a change to their interests in, the Group under the FCA's Disclosure Guidance and Transparency Rules.

-Ends-

Contact details

About Clinigen Group

Clinigen Group plc (AIM: CLIN) is a global pharmaceutical and services company with a unique combination of businesses focused on providing ethical access to medicines. Its mission is to deliver the right medicine to the right patient at the right time through three areas of global medicine supply; clinical trial, unlicensed and licensed medicines. Clinigen acquired Quantum Pharma in November 2017.

For more information, please visit www.clinigengroup.com